The role of glucagon-like peptide-1 agonists in the treatment of multiple sclerosis: a narrative review

HIGHLIGHTS

• What: The study showed that administration of NLY01 at the same time as EAE induction significantly delayed symptom onset and decreased symptom severity (p ≤ 0.0001). The aim of these studies is to evaluate the therapeutic potential of GLP-1 agonists in MS management. The sixth study focused on liraglutide as a neuroprotective agent rather than its effects on EAE symptoms . The seventh study focused on cuprizone-induced MS mice treated with liraglutide .
• Who: Alan D. Kaye and collaborators from the Department of Anesthesiology, Louisiana State University Health Sciences Center, Shreveport, USA School of have . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.